Dr. María-Victoria Mateos, MD, PhD, a consultant hematologist at the University Hospital of Salamanca in Spain, discusses the DREAMM-7 phase 3 trial in this video interview with SOHO Insider.
Dr. Mateos was the lead investigator on the trial, which investigated belantamab mafodotin (blenrep) with bortezomib and dexamethasone (BVd) versus daratumumab with bortezomib and dexamethasone (DVd) in relapsed or refractory patients with multiple myeloma who had at least one prior therapy. Progression-free survival was found to be longer with the BVd combo and, the DREAMM-7 trial also showed sustained benefits across all subgroups including high-risk patients and those refractory to lenalidomide.
Belantamab mafodotin is a BCMA-targeted antibody-drug conjugate. BVd was approved by the FDA on October 23, 2025, for the treatment of adult patients with relapsed or refractory who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.
